

IMPPICT\_JCI\_version\_1

1 **Title:** Ultrasound and biochemical predictors of pregnancy outcome at diagnosis of early-  
2 onset fetal growth restriction

3

4 **Authors and affiliations:**

5 Rebecca Spencer<sup>1,2</sup>, Kasia Maksym<sup>1</sup>, Kurt Hecher<sup>3</sup>, Karel Maršál<sup>4</sup>, Francesc Figueras<sup>5</sup>, Gareth

6 Ambler<sup>6</sup>, Harry Whitwell<sup>1,7,8</sup>, Nuno Rocha Nené<sup>1</sup>, Neil J. Sebire<sup>9</sup>, Stefan R. Hansson<sup>4</sup>, Anke Diemert<sup>3</sup>,

7 Jana Brodzski<sup>4</sup>, Eduard Gratacós<sup>5</sup>, Yuval Ginsberg<sup>1,10</sup>, Tal Weissbach<sup>1,11</sup>, Donald M Peebles<sup>1</sup>, Ian

8 Zachary<sup>12</sup>, Neil Marlow<sup>1</sup>, Angela Huertas-Ceballos<sup>13</sup>, Anna L. David<sup>1</sup>

9

10 <sup>1</sup> UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London,  
11 UK

12 <sup>2</sup> Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

13 <sup>3</sup> Department of Obstetrics and Fetal Medicine, University Medical Center Hamburg-Eppendorf,  
14 Hamburg, Germany

15 <sup>4</sup> Department of Obstetrics and Gynaecology, Institute of of Clinical Sciences Lund, Skane University  
16 Hospital, Lund University, Lund, Sweden

17 <sup>5</sup> Institut D'Investigacions Biomèdiques August Pi í Sunyer, University of Barcelona, Barcelona Center  
18 for Maternal-Fetal and Neonatal Medicine, Barcelona, Spain

19 <sup>6</sup> Department of Statistical Science, University College London, London, UK

20 <sup>7</sup> National Phenome Centre and Imperial Clinical Phenotyping Centre, Department of Metabolism,  
21 Digestion and Reproduction, Imperial College London, London, UK

22 <sup>8</sup> Section of Bioanalytical Chemistry, Division of Systems Medicine, Department of Metabolism,  
23 Digestion and Reproduction, Imperial College London, London, UK

24 <sup>9</sup> Population, Policy & Practice Department, Great Ormond Street Institute of Child Health, University  
25 College London, London, UK

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Page 1

27/01/2023

IMPPICT\_JCI\_version\_1

26 <sup>10</sup> Department of Obstetrics and Gynecology, Rambam Medical Centre, Haifa, Israel

27 <sup>11</sup> Department of Obstetrics and Gynecology, Sheba Medical Center Tel Hashomer, Tel Aviv, Israel

28 <sup>12</sup> Division of Medicine, Faculty of Medical Sciences, University College London, UK

29 <sup>13</sup> Neonatal Department, University College London Hospitals NHS Foundation Trust, London, UK

30

31 **Corresponding author:**

32 **Name:** Rebecca Spencer

33 **Address:** LIGHT Laboratories, University of Leeds, 6 Clarendon Way, Leeds, LS2 9NL

34 Telephone number: 07793 355 359

35 **Email:** r.n.spencer@leeds.ac.uk

36

37 **Conflicts of interest:**

38 RS, KMak, KH, KMar, FF, GA, HW, NRN, NS, SH, AD, EG, YG, TW, IZ and ALD have no conflicts of  
39 interest to declare; NM declares consultancy fees from InfanDx over the past 12 months.

40

41 **Author contributions:**

42 RS contributed to study design, patient recruitment, data collection, sample analysis, data analysis  
43 and writing the manuscript. KMak contributed to patient recruitment and data collection. KH, KMar,  
44 FF, SH, AD, JB, EG, DMP, IZ and ALD contributed to study design, patient recruitment and data  
45 collection. GA contributed to study design and data analysis. HW contributed to sample analysis and  
46 data analysis. NRN contributed to data analysis. NS contributed to study design and sample analysis.  
47 YG and TW contributed to patient recruitment and data collection. NM and AHC contributed to  
48 study design. All authors contributed to critically revising the manuscript, give approval for  
49 publication of the work and agree to be accountable for all aspects of it.

50

51 **Abstract**

52

53 **Background:** Severe early-onset fetal growth restriction (FGR) causes significant fetal and neonatal  
54 mortality and morbidity. Predicting the outcome of affected pregnancies at the time of diagnosis is  
55 difficult, preventing accurate patient counselling. We investigated the use of maternal serum protein  
56 and ultrasound measures at diagnosis to predict fetal or neonatal death and three secondary  
57 outcomes: fetal death or delivery  $\leq 28+0$  weeks; development of abnormal umbilical artery Doppler  
58 velocimetry; slow fetal growth.

59 **Methods:** Women with singleton pregnancies (n=142, estimated fetal weights [EFWs]  $< 3^{\text{rd}}$  centile,  
60  $< 600\text{g}$   $20+0$ - $26+6$  weeks of gestation, no known chromosomal, genetic or major structural  
61 abnormalities), were recruited from four European centres. Maternal serum from the discovery set  
62 (n=63) was analysed for seven proteins linked to angiogenesis, 90 additional proteins associated  
63 with cardiovascular disease and five proteins identified through pooled liquid chromatography  
64 tandem mass spectrometry. Patient and clinician stakeholder priorities were used to select models  
65 tested in the validation set (n=60), with final models calculated from combined data.

66 **Results:** The most discriminative model for fetal or neonatal death included EFW z-score (Hadlock 3  
67 formula/Marsal chart), gestational age and umbilical artery Doppler category (AUC 0.91, 95%CI 0.86-  
68 0.97) but was less well calibrated than the model containing only EFW z-score (Hadlock3/Marsal).  
69 The most discriminative model for fetal death or delivery  $\leq 28+0$  weeks included maternal serum  
70 placental growth factor (PIGF) concentration and umbilical artery Doppler category (AUC 0.89, 95%CI  
71 0.83-0.94).

72 **Conclusion:** Ultrasound measurements and maternal serum PIGF concentration at diagnosis of  
73 severe early-onset FGR predict pregnancy outcomes of importance to patients and clinicians.

74 **Trial registration:** ClinicalTrials.gov NCT02097667

75 **Funding:** European Union, Rosetrees Trust, Mitchell Charitable Trust.

## 76 **Introduction**

77 The survival and growth of a fetus depends on placental provision of nutrients and waste exchange  
78 with the mother. When this system is impaired, by inadequate transformation of the uteroplacental  
79 circulation or deficits in the structure or function of the placenta, the fetus fails to reach their  
80 growth potential (1, 2). The resulting fetal growth restriction (FGR) may be diagnosed antenatally on  
81 the basis of an ultrasound determined low estimated fetal weight (EFW) for gestational age; either  
82 <3<sup>rd</sup> centile or <10<sup>th</sup> centile with abnormal Doppler ultrasound indices in the uterine (UtA) and/or  
83 umbilical (UmA) arteries (3) (4, 5). Early-onset FGR, occurring before 32 weeks of gestation, carries  
84 significant risks of stillbirth, neonatal morbidity and mortality, neurodevelopmental impairment, and  
85 long-term health problems (6-13). There is currently no treatment that can improve fetal growth in  
86 utero; instead, management involves monitoring the pregnancy and timing delivery to balance the  
87 risks of stillbirth and prematurity (4, 14-16).

88

89 An important question when developing novel therapies for early-onset FGR is which pregnancies to  
90 include in early-phase clinical trials. There is a balance to be struck between identifying pregnancies  
91 that are sufficiently severely affected to justify the possible risks of the intervention but not so  
92 severely affected that there is no potential to determine efficacy. Numerous studies have  
93 investigated predictive markers for the development of FGR (17-22), but far fewer have studied the  
94 prediction of pregnancy outcome when early-onset FGR is diagnosed. Lack of knowledge about  
95 pregnancy outcome in FGR makes it difficult to optimise the inclusion criteria for clinical trials, but it  
96 also leaves pregnant patients and their partners with a considerable burden of uncertainty (23, 24).

97

98 The EVERREST Project aims to carry out a phase I/IIa trial of maternal vascular endothelial growth  
99 factor (VEGF) gene therapy for early-onset FGR (25). The greatest potential for benefit is in  
100 pregnancies at the threshold of viability, for whom our current management option, preterm


101 delivery, is not possible or is very high risk. In preparation for a clinical trial of a novel therapeutic,  
102 we established a multicentre prospective study to characterise the natural history of early-onset  
103 FGR, choosing an extreme phenotype in which the estimated fetal weight (EFW) was <3<sup>rd</sup> centile and  
104 <600g between 20+0 and 26+6 weeks of gestation (henceforth referred to as 'severe' early-onset  
105 FGR) (26).

106  
107 The aim of this work was to prospectively identify and validate ultrasound and serum biochemical  
108 factors that could be used to predict fetal or neonatal death in pregnancies affected by severe early-  
109 onset FGR. These could subsequently be used to select the most appropriate women for a first-in-  
110 human study of a novel therapeutic to treat FGR, and to better counsel women and their partners  
111 about pregnancy outcome. To this end, we asked patients and clinicians to assess the value of our  
112 primary and secondary outcomes, based on which we then selected models for validation.  
113 Unsupervised parentlitic network analysis by pregnancy outcome and functional network analysis of  
114 proteins associated with pregnancy outcomes were also performed to maximise the utility of the  
115 proteomic data with the aim of providing insights into the underlying pathophysiology.

## 116 **Results**

117 The discovery set, recruited between March 2014 and September 2016, comprised 63 pregnant  
118 participants (Figure 1 & Table 1; supplementary data Table 1). Follow-up for the ascertainment of  
119 study outcomes was completed in November 2016. The validation set, recruited between October  
120 2016 and January 2020, comprised 60 pregnant participants, with follow-up for the ascertainment of  
121 study outcomes completed in March 2020. There were no significant differences in maternal  
122 demographics, pregnancies characteristics or pregnancy outcomes between the discovery and  
123 validation sets (Table 1; supplementary data Table 2 & Figure 1). Overall, 42 (34%) of the  
124 pregnancies ended in the primary outcome of fetal or neonatal death (within the first 28 days of  
125 life). For the three secondary outcomes, only fetal death or delivery  $\leq 28+0$  weeks of gestation could

126 be ascertained for all pregnancies, occurring in 58 cases (47%). The UmA Doppler velocimetry was  
127 normal (<95<sup>th</sup> centile for gestation (27)) at enrolment in 46 participants, of whom 21 (46%)  
128 subsequently developed abnormal UmA Doppler measurements. Fetal growth trajectory (based on  
129 change in percentage weight deviation over a period of two weeks or more (28)) could be assessed  
130 for 104 pregnancies (85%), with the remaining pregnancies ending in fetal death or delivery before a  
131 2-week interval was reached. Forty-one of these 104 fetuses (39%) demonstrated slow fetal growth  
132 (worsening of weight deviation of  $\geq 10$  percentage points). A smaller proportion of fetuses  
133 demonstrated slow fetal growth in the validation set (31%) than in the discovery set (47%).  
134



135

136 Figure 1: Flow diagram of participant eligibility and enrolment across the four EVERREST Prospective  
137 Study centres from 10th March 2014 to 30th January 2020 for the discovery and validation sets.

138

139

IMPPICT\_JCI\_version\_1

140 Table 1: Characteristics and outcomes of the discovery, validation and combined participant sets.  
 141 Discovery and validation sets were compared using 2-sided t tests for symmetrical continuous  
 142 variables, Mann-Whitney U tests for skewed continuous variables and chi square or Fisher's exact  
 143 tests (where specified) for categorical variables.

	Discovery n=63	Validation n=60	p value	Combined n=123
<b>Maternal characteristics</b>				
Maternal age, mean years (SD)	33.7 (6.0)	33.3 (6.7)	0.72	33.5 (6.3)
Primiparous, n (%)	43 (68)	37 (62)	0.44	80 (65)
BMI, median (IQR)	24.9 (22.7-28.6)	26.4 (22.8-31.0)	0.36	25.7 (22.8-30.0)
Ethnicity, n (%) <sup>1</sup>				
White	42 (67)	27 (46)	0.16	69 (57)
Black	10 (16)	15 (25)		25 (20)
Asian	10 (16)	15 (25)		25 (20)
Other	1 (2)	2 (3)		3 (2)
Essential hypertension, n (%)	10 (16)	6 (10)	0.33	16 (13)
Pre-eclampsia at enrolment, n (%) <sup>#</sup>	4 (6)	5 (8)	0.47	9 (7)
<b>Enrolment ultrasound measurements</b>				
Gestational age at enrolment, median weeks+days (IQR) [range]	23+6 (22+3-25+1) [20+1-26+5]	23+5 (22+3-24+4) [20+4-26+4]	0.48	23+5 (22+3-24+5) [20+1-26+5]
EFW at enrolment, median grams (IQR) (29)	392 (281-503)	387 (280-448)	0.61	389 (281-484)
EFW z-score at enrolment, median (IQR) (29, 30)	-3.0 (-3.6 to -2.5)	-3.2 (-3.8 to -2.7)	0.17	-3.1 (-3.7 to -2.6)
Mean UtA PI >95 <sup>th</sup> centile at enrolment, n (%) <sup>2</sup> (27)	49 (79)	49 (82)	0.71	98 (80)
UmA PI >95 <sup>th</sup> centile at enrolment, n (%) <sup>3</sup> (27)	32 (51)	36 (60)	0.26	78 (55)
Absent or reversed UmA end-diastolic flow at enrolment, n (%) <sup>3</sup>	18 (29)	25 (42)	0.11	43 (35)
MCA PI <5 <sup>th</sup> centile at enrolment, n (%) <sup>4</sup> (27)	10 (16)	7 (12)	0.41	17 (15)
DV a wave absent or reversed at enrolment, n (%) <sup>5#</sup>	5 (8)	4 (7)	0.51	9 (8)
<b>Pregnancy outcomes</b>				
Pre-eclampsia at any point in pregnancy, n (%) <sup>6</sup>	24 (39)	17 (33)	0.51	41 (36)
Gestational age at diagnosis of stillbirth or delivery of live birth, median weeks+days (IQR) [range]	28+2 (26+3-34+0) [21+4-39+3]	28+2 (26+4-33+2) [22+2-39+6]	0.90	28+2 (26+3-33+2) [22+2-39+6]
Female fetus / infant, n (%) <sup>7</sup>	36 (57)	24 (43)	0.19	60 (50)
Caesarean delivery, n (%)	42 (67)	37 (63)	0.65	79 (65)
Live births, n (%)	47 (75)	43 (72)	0.71	90 (73)
	n=47	n=43		n=90
Live births ≤28+0 weeks, n (%)	15 (32)	14 (33)	0.95	29 (32)
Live births >37 weeks, n (%)	8 (17)	10 (23)	0.46	18 (20)
Caesarean delivery for live births, n (%)	42 (89)	37 (88)	0.85	79 (89)
Neonatal deaths, n (%) <sup>#</sup>	5 (11)	4 (9)	0.56	9 (10)

Birth weight z-score for live births, mean (SD) (30)	-3.5 (1.1)	-3.5 (0.9)	0.97	-3.5 (1.0)
Study outcomes				
	<i>n</i> =63	<i>n</i> =60		<i>n</i> =123
Fetal or neonatal death, n (%)	21 (33)	21 (35)	0.85	42 (34)
Death or delivery $\leq 28+0$ weeks of gestation, n (%)	30 (48)	28 (47)	0.92	58 (47)
	<i>n</i> =55	<i>n</i> =49		<i>n</i> =104
Slow fetal growth, n (%)	26 (47)	15 (31)	0.083	41 (39)
	<i>n</i> =26	<i>n</i> =20		<i>n</i> =46
Development of UmA PI $>95^{\text{th}}$ centile, n (%)	12 (46)	9 (45)	0.94	21 (46)

144 <sup>1</sup>*n*=1 missing from validation, <sup>2</sup>*n*=1 missing from discovery, <sup>3</sup>*n*=1 missing from validation, <sup>4</sup>*n*=5  
 145 missing from discovery and *n*=1 missing from validation, <sup>5</sup>*n*=3 missing from discovery and *n*=1  
 146 missing from validation, <sup>6</sup>*n*=1 missing from discovery and *n*=8 missing from validation, <sup>7</sup>*n*=5 missing  
 147 from validation, #Fisher's exact test. DV=ductus venosus, EFW=estimated fetal weight, MCA=middle  
 148 cerebral artery, PI=pulsatility index, UmA=umbilical artery, UtA=uterine artery.

149

150 **Ultrasound measurements as predictors of fetal or neonatal death and death or delivery  $\leq 28+0$**

151 **weeks of gestation in the discovery set:** The best ultrasound predictor of fetal or neonatal death

152 was EFW z-score, either as calculated using the Hadlock 3 formula and Marsal chart (EFW<sub>HM</sub>: AUC

153 0.81, 95% CI 0.69-0.93) or the Intergrowth formula and chart (EFW<sub>Int</sub>: AUC 0.83, 95% CI 0.71-0.95).

154 UmA category (<95th centile; >95th centile with positive EDF; absent EDF; reversed EDF. AUC 0.75,

155 95% CI 0.62-0.88) and slow fetal growth (AUC 0.70, 95% CI 0.56-0.83) were also fair predictors. UmA

156 category was the best predictor of death or delivery  $\leq 28+0$  weeks (AUC 0.80, 95% CI 0.70-0.91), with

157 mean UtA PI (AUC 0.77, 95% CI 0.65-0.89) and Intergrowth EFW z-score (AUC 0.73, 95% CI 0.60-0.85)

158 also fair predictors (supplementary data Tables 3 & 4).

159 **Proteomics:** Mass spectrometry (MS) profiling of pooled samples gave quantitative information for

160 200 protein groups (sets of proteins that cannot be distinguished based on peptide sequences), from

161 which human placental lactogen (HPL), fibronectin, pregnancy-specific beta-1 glycoprotein (PSG1),


162 serum amyloid A (SAA) and leucyl-cystinyl aminopeptidase (LNPEP) were selected for individual

163 validation, based on the scoring system outlined in the methods.




164 **Univariate associations between maternal serum protein concentrations and outcomes in the**  
165 **discovery set:** Four proteins were undetectable in most of the samples: VEGF-A, natriuretic peptides  
166 B (BNP), melusin, poly[ADP-ribose] polymerase 1 (PARP1). These were excluded from further  
167 prediction analyses. The associations between the remaining 98 proteins and the four pregnancy  
168 outcomes are summarised in Figure 2. Placental growth factor (PIGF) and HPL concentration were  
169 significantly associated with fetal or neonatal death (after Benjamini-Hochberg correction), with  
170 fold-changes of 0.52 in pregnancies ending in fetal or neonatal death compared with pregnancies  
171 ending in neonatal survival. The concentrations of nine proteins were significantly associated with  
172 death or delivery  $\leq 28+0$  weeks (after correction). The greatest magnitudes of fold-changes were  
173 seen for PIGF (0.28), HPL (0.45), and PSG1 (0.48).  
174

175



176




177

178 Figure 2: Volcano plots showing the statistical significance and magnitude of the associations  
179 between the 98 proteins and four pregnancy outcomes in the discovery set. Associations tested with  
180 2-sided t tests for symmetrical data and Mann-Whitney U tests for skewed data. Dotted line  
181 indicates a p value of 0.05. Dashed line indicates the Benjamini-Hochberg cut-off with a 5% false  
182 discovery rate ( $p=0.0015$  for fetal or neonatal death,  $p=0.005$  for death or delivery  $\leq 28+0$  weeks).  
183 See supplementary data Table 5 for full protein names.

184

185

186 **Parenclitic network analysis of the discovery set:** Both the networks for fetal or neonatal death and  
187 death or delivery  $\leq 28+0$  weeks contained clusters centred around HPL (clusters 6 and 4, Figure 3).  
188 These clusters also contained pentraxin-related protein PTX3, spondin-2 (SPON2) and  
189 thrombomodulin (TM) and contained or were linked to decorin (DCN). The network for death or  
190 delivery  $\leq 28+0$  weeks also contained a cluster centred around PIGF (cluster 2). For all three of the  
191 networks that included fetal sex, similar clusters emerged that contained renin (REN), angiotensin 1  
192 (ANG1), dickkopf-related protein 1 (DKK1) and platelet-derived growth factor subunit beta (PDGFB),  
193 contained or were linked to pregnancy-associated plasma protein A (PAPP-A) and in two of the three  
194 networks included lectin-like oxidized LDL receptor 1 (LOX1). Networks and associated dendrograms  
195 for the development of abnormal umbilical artery Dopplers and slow fetal growth are provided in  
196 supplementary data Figures 4 & 5.  
197



198

199

200


201

202

203

Figure 3: Parental networks for clusters generated based on: (A) fetal or neonatal death (B) death or delivery  $\leq 28+0$  weeks. See supplementary data Table 5 for full protein names and supplementary data Figures 2 & 3 for associated dendrograms.

204 **Model selection by stakeholders:** None of the single variable or multivariable models for predicting  
 205 slow fetal growth performed well enough to warrant validation (AUCs <0.70). For the three  
 206 remaining outcomes, an online survey was performed to ascertain the priorities of clinicians and  
 207 patients in predicting outcomes. Forty-five clinicians from 18 countries (of 173 contacted, 26%) and  
 208 seven patients from the UK who had experienced a pregnancy complicated by severe early-onset  
 209 FGR (of 36 contacted, 19%) responded (supplementary data Table 6). The prediction of fetal or  
 210 neonatal death and death or delivery  $\leq 28+0$  weeks were considered important or very important by  
 211 all patients and were also rated highly by clinicians for the purposes of patient counselling and  
 212 clinical management (Figure 4). Patients and clinicians marginally prioritised sensitivity over  
 213 specificity for most outcomes (supplementary data Figure 6). For the prediction of the development  
 214 of abnormal UmA PI, patients universally prioritised sensitivity while clinicians marginally prioritised  
 215 specificity for patient counselling.



Key	Very important	Important
Patient priorities	71%	29%
Clinical management	59%	27%
Patient counselling	16%	32%

229  
 230 Figure 4: The proportion of patients who ranked our three pregnancy outcomes as 'important' or  
 231 'very important' and the proportion of clinicians who ranked them as 'important' or 'very important'  
 232 for clinical management and for patient counselling. UmA PI=umbilical artery pulsatility index.

233

IMPPICT\_JCI\_version\_1

234 Based on the survey results, the model performance metrics and the assay reliability, models  
235 containing the variables listed in Tables 2 and 3 were selected for validation. For the prediction of  
236 death or delivery  $\leq 28+0$  weeks, models including HPL marginally outperformed models including  
237 PIGF. However, possibly related to the short processing time, the commercial HPL ELISA had high  
238 intra-assay variability in our hands (mean coefficient of variation 8.0%, SD 7.3%, 28% requiring  
239 repeat analysis for coefficient of variation  $>10\%$ ). Because of this, and the existence of clinically  
240 approved tests for PIGF, models including PIGF were selected for validation.

241 **Model validation:** Five of the seven protein models (Table 2) and all five of the models containing  
242 ultrasound measurements (Table 3), generated in the discovery set, were successfully validated,  
243 with AUCs included in the AUC 95% CIs generated from the discovery cross-validation estimates.

244 **Addition of pregnancy characteristics:** Validated models were not significantly improved by the  
245 addition of maternal BMI, maternal age, maternal ethnicity or fetal sex. Adding gestational age at  
246 enrolment significantly improved the models containing EFW<sub>HM</sub> alone (LR test  $p=0.0001$ ) and EFW<sub>HM</sub>  
247 with UmA category (LR test  $p<0.00005$ ) to predict fetal or neonatal death (supplementary data Table  
248 7). The addition of 'pre-eclampsia at enrolment' significantly improved all validated models  
249 predicting fetal death or delivery  $\leq 28$  weeks of gestation (supplementary data Table 7).

250 **PIGF values for maximum likelihood ratios:** Receiver operating characteristic (ROC) curves are  
251 shown in Figures 5 and 6. Model constants and coefficients, along with optimal cut points for  
252 positive and negative likelihood ratios and correct classification are provided in supplementary data  
253 Tables 8 and 9. Serum PIGF concentration  $<14.2$  pg/ml predicted fetal or neonatal death with a  
254 positive likelihood ratio of 18.3, sensitivity of 45% and specificity of 98% and correctly classified 80%  
255 of participants. Serum PIGF concentration  $<14.5$  pg/ml predicted death or delivery  $\leq 28+0$  weeks with  
256 a positive likelihood ratio of 24.7, sensitivity of 38% and specificity of 98% and correctly classified  
257 70% of participants.

258

259 Table 2: Model validation for predicting adverse pregnancy outcomes: the seven pre-specified  
 260 models containing maternal serum proteins. The model not validated is shaded. Validated models  
 261 include estimates from the combined discovery and validation sets.

Outcomes	Variable(s)	Discovery (with LOOCV)		Validation		Combined	
		AUC	95% CI	AUC	95% CI	AUC	95% CI
Fetal or neonatal death	PIGF	0.75	0.62-0.88	0.83	0.72-0.95	0.81	0.73-0.89
	PIGF & lymphotactin	0.84	0.73-0.95	0.75	0.62-0.88	0.83	0.75-0.91
	PIGF, lymphotactin & fibronectin	0.85	0.74-0.96	0.69	0.55-0.83		
Death or delivery $\leq 28+0$ weeks	PIGF	0.86	0.76-0.96	0.76	0.64-0.88	0.82	0.75-0.89
	PIGF & pre-eclampsia					0.84	0.77-0.91
	PIGF & PSG1*	0.91	0.82-0.99	0.80	0.69-0.91	0.86	0.80-0.93
	PIGF, PSG1 & pre-eclampsia					0.88	0.82-0.94
Development of abnormal UmA PI	PIGF	0.84	0.50-0.95	0.64	0.38-0.89	0.78	0.64-0.91
	PIGF & fibronectin	0.88	0.74-1.00	0.65	0.39-0.90	0.80	0.67-0.93

262 \*Discovery AUC 0.906, validation 95% CI 0.688-0.912. LOOCV=leave-one-out cross-validation,  
 263 PI=pulsatility index, PIGF=placental growth factor, PSG1=pregnancy-specific beta-1 glycoprotein,  
 264 UmA=umbilical artery. Models were generated and tested using the natural log of PIGF in pg/ml and  
 265 centered and scaled values for lymphotactin normalised protein expression (NPX) on a log2 scale.

266

267

268 Table 3: Model validation for predicting adverse pregnancy outcomes: models containing ultrasound  
 269 measurements, maternal serum protein concentrations and pregnancy characteristics, and their  
 270 final AUCs from the combined discovery and validation sets.


Outcomes	Variable(s)	Discovery (with LOOCV)		Validation		Combined	
		AUC	95% CI	AUC	95% CI	AUC	95% CI
Fetal or neonatal death	EFW <sub>HM</sub> z-score	0.78	0.66-0.91	0.89	0.80-0.97	0.85	0.78-0.92
	EFW <sub>HM</sub> z-score & GA					0.90	0.84-0.96
	EFW <sub>Int</sub> z-score	0.80	0.67-0.93	0.91	0.83-0.99	0.87	0.80-0.94
	EFW <sub>HM</sub> z-score & UmA category <sup>1</sup>	0.78	0.64-0.91	0.88	0.80-0.97	0.86	0.79-0.93
	EFW <sub>HM</sub> z-score, UmA category & GA <sup>1</sup>					0.91	0.86-0.97
Death or delivery ≤28+0 weeks	UmA category <sup>1</sup>	0.78	0.67-0.89	0.79	0.68-0.91	0.80	0.72-0.88
	UmA category & pre-eclampsia <sup>1</sup>					0.84	0.77-0.91
	UmA category & PIGF <sup>1</sup>	0.89	0.81-0.97	0.85	0.75-0.94	0.89	0.83-0.94
	UmA category, PIGF & pre-eclampsia <sup>1</sup>					0.90	0.85-0.95

271 <sup>1</sup>n=1 missing from validation set. EFW<sub>HM</sub>=estimated fetal weight calculated using Hadlock 3 formula  
 272 (29) with z-score calculated using Marsal reference chart (30), EFW<sub>Int</sub>=estimated fetal weight and z-  
 273 score calculated using Intergrowth formulae (31), GA=gestational age at enrolment in days,  
 274 LOOCV=leave-one-out cross-validation, PIGF=placental growth factor, UmA=umbilical artery.

275




IMPPICT\_JCI\_version\_1



276

277 Figure 5: Comparison of the receiver operating characteristic (ROC) curves for the models predicting  
278 fetal or neonatal death. EFW-HM=estimated fetal weight calculated using Hadlock 3 formula (29)  
279 with z-score calculated using Marsal reference chart (30), EFW-Intergrowth=estimated fetal weight  
280 and z-score calculated using Intergrowth formula and reference chart (31), GA=gestational age at  
281 enrolment, PIGF=placental growth factor concentration, UmA=umbilical artery Doppler category  
282 (0=pulsatility index <95th centile, 1=pulsatility index >95th centile, 2=absent end-diastolic flow,  
283 3=reversed end-diastolic flow).



284


285 Figure 6: Comparison of the receiver operating characteristic (ROC) curves for the models predicting  
286 fetal death or delivery  $\leq 28+0$  weeks of gestation. PET=pre-eclampsia at enrolment, PIGF=placental  
287 growth factor concentration, PSG1=pregnancy-specific glycoprotein 1 normalised protein  
288 expression, UmA=umbilical artery Doppler category (0=pulsatility index <95th centile, 1=pulsatility  
289 index >95th centile, 2=absent end-diastolic flow, 3=reversed end-diastolic flow).

290

291 **Alternative EFW formulae:** Although the EFW z-score calculated using the Intergrowth formula and  
292 chart gave the highest AUC for predicting fetal or neonatal death, the Intergrowth formula for  
293 estimating fetal weight performed poorly in our sample, especially at lower fetal weights. For the 21  
294 livebirths with a birthweight <600g and an EFW performed within seven days of delivery, the  
295 Intergrowth formula overestimated birthweight by a mean of 47% (SD 14%), in contrast to the  
296 Hadlock 3 formula which overestimated birthweight by a mean of 25% (SD 10%, supplementary data  
297 Figure 8). For all 67 livebirths with an EFW performed within seven days of delivery, the Intergrowth  
298 formula overestimated birthweight by a mean of 29% (SD 20%) and the Hadlock 3 formula  
299 overestimated birthweight by a mean of 15% (SD 13%). As might be expected, using the EFW  
300 calculated from one formula in the model derived from the other had a substantial negative impact  
301 on calibration (supplementary data Figure 9).

302 **Re-analysis of the combined sets:** Combining the centred and scaled data from the discovery and  
303 validation sets, the strongest associations with both fetal or neonatal death, and death or delivery  
304  $\leq 28+0$  weeks were the previously observed negative associations with PIGF ( $p=1.4 \times 10^{-8}$  and  
305  $p=3.0 \times 10^{-11}$ ) and HPL ( $p=1.3 \times 10^{-7}$  and  $p=1.4 \times 10^{-10}$ ) (Figure 7). The evidence for the negative  
306 association between PSG1 and both outcomes was strengthened, as was the evidence for negative  
307 associations between matrix metalloproteinase-12 (MMP12) and programmed cell death 1 ligand 2  
308 (PDL2) and death or delivery  $\leq 28+0$  weeks. None of the proteins showed an association with the  
309 development of abnormal UmA Dopplers or slow fetal growth at a Benjamini-Hochberg 5% false  
310 discovery rate (supplementary data Figure 10).

311



312


313 Figure 7: Volcano plots showing the statistical significance and magnitude of associations between  
 314 fetal and neonatal death and death or delivery  $\leq 28+0$  weeks and the centred and scaled  
 315 concentrations of the 93 proteins from the discovery and validation sets combined. Associations  
 316 tested with 2-sided t tests. Dotted line indicates  $p=0.05$ , short-dashed line indicates Benjamini-  
 317 Hochberg cut-off with a 5% false discovery rate (A  $p=0.0048$ , B  $p=0.012$ ), long-dashed line indicates  
 318 Benjamini-Hochberg cut-off with a 1% false discovery rate (A  $p=0.00032$ , B  $p=0.0013$ ). See  
 319 supplementary data Table 10 for full protein names and individual  $-\log_{10} p$  values.

320

321 Functional analysis of the proteins associated with fetal or neonatal death at a 5% false discovery  
 322 rate demonstrated co-expression of HPL and GH. Expanding the network to include intervening  
 323 proteins resulted in clusters sharing GO biological processes of growth hormone receptor signalling,  
 324 VEGF signalling and calcitonin family receptor signalling, with proteins in the latter two clusters also  
 325 involved in angiogenesis and regulation of angiogenesis (Figure 8). Proteins associated with death or

IMPPICT\_JCI\_version\_1


326 delivery  $\leq 28+0$  weeks showed multiple interactions, predominantly centred on fibronectin. Shared  
327 GO biological processes included those relating to growth (regulation of angiogenesis, cellular  
328 response to growth factors and growth hormone receptor signalling pathway via jak-stat), immune  
329 function (leucocyte migration, inflammatory response, and positive regulation of T cell activation) or  
330 both (regulation of cell adhesion, positive regulation of nik/NF-kappaB signalling) (Figure 9).  
331




332  
333 Figure 8: An expanded functional network demonstrating interactions and shared GO biological  
334 processes of the proteins associated with fetal or neonatal death in the combined data set at a  
335 Benjamini-Hochberg false discovery rate of 5%. Red=growth hormone receptor signalling pathway,  
336 yellow=vascular endothelial growth factor signalling pathway, green=calcitonin family receptor  
337 signalling pathway, light blue=regulation of angiogenesis, dark blue=angiogenesis. See  
338 supplementary data Table 5 for full protein names. Analysis, graphic and legend from STRING (Swiss  
339 Institute of Bioinformatics)(32).

340

IMPPICT\_JCI\_version\_1



341



342

Figure 9: Functional interactions and shared GO biological processes of the proteins associated with death or delivery  $\leq 28+0$  weeks in the combined data set at a Benjamini-Hochberg false discovery rate of 5%. Red=growth hormone receptor signalling pathway via jak-stat, orange=inflammatory response, yellow=leukocyte migration, light green=extracellular matrix, dark green=regulation of cell adhesion, light blue=regulation of angiogenesis, dark blue=cellular response to growth factor stimulus, pink=positive regulation of nik/NF-kappaB signalling, purple=positive regulation of T cell activation. See supplementary data Table 5 for full protein names. Analysis, graphic and legend from STRING (Swiss Institute of Bioinformatics)(32).

350

351

The three best performing LOOCV models using the combined centred and scaled data all included pro-adrenomedullin (ADM) for predicting fetal or neonatal death, PIGF and HPL for predicting death or delivery  $\leq 28+0$  weeks and Platelet-derived growth factor subunit B (PDGFB) for predicting the development of abnormal UmA Doppler measurements (supplementary data Table 12). The emergence of ADM in the models predicting fetal or neonatal death was consistent with the significant association present in the combined but not the discovery sets. In contrast, PDGFB did

356

IMPPICT\_JCI\_version\_1

357 not show significant univariate associations with the development of abnormal UmA Dopplers in the  
358 discovery, validation, or combined data sets.

359 **Predicting gestational age of livebirth or diagnosis of fetal death and interval from enrolment to**

360 **livebirth or diagnosis of fetal death:** Twelve protein and ultrasound measurements showed an

361 association with the gestational age at which the pregnancies ended in livebirth or fetal death, at a

362 1% Benjamini-Hochberg false discovery rate (supplementary data Table 13). The best model to

363 predict gestational age at livebirth or fetal death included PIGF and sflt1 concentrations, MMP12 and

364 IL1RL2 NPX and UmA category at enrolment (Figure 10). Eight protein and ultrasound measurements

365 showed an association with the interval between enrolment and either livebirth or the diagnosis of

366 fetal death at a 1% Benjamini-Hochberg false discovery rate (supplementary data Table 13). The best

367 model to predict the interval between enrolment and livebirth or fetal death included PIGF and sflt1

368 concentrations, MMP12 and decorin NPX, UmA category and gestational age at enrolment (Figure

369 10). Both models accounted for 68% of the variation in the outcomes they were predicting but had

370 95% prediction intervals of 40 days, limiting their clinical utility. Sparser models, including PIGF and


371 sflt1 concentrations and UmA category to predict gestational age at livebirth or fetal death, and

372 these same variables plus gestational age at enrolment to predict interval to livebirth or fetal death,

373 had only slightly wider 95% prediction intervals of 42 days (supplementary data Figure 11).

374

IMPPICT\_JCI\_version\_1



375

376 Figure 10: (A) Predicted versus actual gestational age of either livebirth or diagnosis of fetal death,  
377 based on the model containing PIGF and sflt1 concentrations, decorin and matrix metalloproteinase  
378 12 normalised protein expression and umbilical artery Doppler category. (B) Predicted versus actual  
379 interval from enrolment to either livebirth or diagnosis of fetal death, based on the model  
380 containing PIGF and sflt1 concentrations, decorin and matrix metalloproteinase 12 normalised  
381 protein expression, umbilical artery Doppler category and gestational age at enrolment. Green filled  
382 circles=pregnancies ending in livebirth, red hollow circles=pregnancies ending in fetal death, dotted  
383 lines=95% prediction intervals.

384

385 **Placental histological classification:** Placental samples for histological examination were available  
386 for 55 pregnancies (45%); these had similar characteristics and outcomes to the pregnancies without  
387 available samples (supplementary data Tables 14 & 15). The only statistically significant difference  
388 was a higher proportion of female fetuses among the pregnancies that had placental samples than  
389 those that did not (63% vs 41%,  $p=0.016$ ). Forty-five (82%) placentas showed evidence of placental  
390 pathology, with 39 (71%) classified as maternal vascular malperfusion (MVM), three (5%) as villitis of  
391 unknown aetiology (VUE), one (2%) as fetal vascular malperfusion (FVM) and two (4%) as non-  
392 specific dysmorphic villi. Twelve of the 14 placental samples from pregnancies ending in stillbirth  
393 showed MVM, while the three available samples from pregnancies ending in neonatal death showed



IMPPICT\_JCI\_version\_1

394 VUE, FVM and dysmorphic villi. Mean UtA PI, maternal serum PIGF and maternal serum PAPP-A at  
395 enrolment all differed significantly between pregnancies with subsequent MVM and pregnancies  
396 without MVM. In contrast, none of the umbilical artery parameters studied (UmA category at  
397 enrolment; the occurrence of UmA PI >95<sup>th</sup> centile at any point before delivery; the occurrence of  
398 absent or reversed UmA end-diastolic flow at any point before delivery) showed evidence of an  
399 association with placental histological classification of MVM (supplementary data Table 16).

## 400 **Discussion**

### 401 **Principle findings and significance**

402 To our knowledge this is the first study to use a discovery science approach, combining ultrasound  
403 and biochemical parameters, to identify and validate prognostic markers at the time of diagnosis of  
404 severe early-onset FGR. These findings can be used to inform personalised counselling and  
405 management of affected pregnancies with outcomes of importance to patients and clinicians.  
406 Furthermore, by providing alternative thresholds that prioritise positive and negative likelihood  
407 ratios and maximum correct categorisation, eligibility criteria for clinical trials of novel therapeutics  
408 can be adapted depending on the perceived risk: benefit ratio of the intervention.

409 Our secondary analyses, including parenclitic network analysis, functional enrichment analysis and  
410 triangulation with placental histological classification, provide a deeper characterisation of this  
411 unique case series. Some of these findings support and enhance our existing understanding of  
412 placental FGR, such as the interplay between angiogenesis, immune cells, and the extracellular  
413 matrix (33-35). Other findings offer new avenues for investigation, such as the parenclitic network  
414 cluster around fetal sex, which includes proteins related to pericyte function (36).

415

### 416 **Findings in the context of existing literature**

417 Given that ultrasound assessment of biometry and Doppler velocimetry forms the mainstay of  
418 identifying and monitoring FGR, it is unsurprising that EFW z-score and umbilical artery category



IMPPICT\_JCI\_version\_1

419 were validated as predictors of fetal or neonatal death and fetal death or delivery  $\leq 28+0$  weeks  
420 respectively (37-39). A secondary analysis of 105 pregnancies from the UK placebo-controlled trial of  
421 sildenafil citrate for early-onset FGR (STRIDER; EFW or AC  $< 10^{\text{th}}$  centile with absent or reversed UMa  
422 end-diastolic flow at 22+0-29+6 weeks) identified EFW as an independent predictor of livebirth (OR  
423 per 100g 4.3, 95%CI 2.3-8.0,  $p < 0.001$ ) and overall survival (OR per 100g 2.9, 95%CI 1.8-4.4,  
424  $p < 0.001$ )(40). What is less expected is that absent or reversed ductus venosus a wave was a poor  
425 predictor of fetal or neonatal death in our participants (AUC 0.59, 95% CI 0.53-0.66, see  
426 supplementary material Table 4), in contrast to the results of previous studies (41, 42). This may  
427 reflect a change in clinical practice since these studies were published. Their findings led to ductus  
428 venosus waveform becoming an important factor in timing of delivery in extremely pre-term FGR  
429 (14, 43), which may have altered the natural history of the disease by prompting delivery before  
430 stillbirth could occur.

431 A limitation of using ultrasound parameters is their potential for variation. In the case of Doppler  
432 velocimetry this includes interobserver variability, temporal variation due to factors such as  
433 maternal and fetal movement, and variation in umbilical artery waveforms between arteries and  
434 along the length of the cord (44-47). There is also considerable variation between different Doppler  
435 reference ranges, both in terms of the values of their 'normal' ranges and their methodological  
436 quality(48). In the case of EFW z-score, variation arises from interobserver variability in measuring  
437 biometry, variation in formulae used to generate the EFW and variation in charts used to determine  
438 the z-score for gestational age (49-51). Despite the methodological limitations of the Hadlock 3  
439 formula, a recent study of 65 pregnancies with early-onset FGR delivered within seven days of  
440 ultrasound assessment found it gave a better combination of systematic and random error than 20  
441 other formulae tested (52).

442 Several recent studies have highlighted the potential utility of PIGF concentration to predict  
443 outcomes in SGA and FGR pregnancies. In a case series of 173 singleton pregnancies with a

IMPPICT\_JCI\_version\_1

444 customised EFW <10<sup>th</sup> centile between 20+0 and 31+6 weeks, the sflt1/PIGF ratio at diagnosis was  
445 an excellent predictor of delivery <30 weeks (AUC 0.96, 95% CI 0.93->0.99) and <34 weeks (AUC  
446 0.94, 95% CI 0.89-0.98) and a good predictor of a composite adverse perinatal outcome (AUC 0.83,  
447 95% CI 0.77-0.90) (53). Similarly, in 116 singleton pregnancies with early-onset FGR (customised EFW  
448 <3<sup>rd</sup> centile or customised EFW <10<sup>th</sup> centile with abnormal UmA and/or UtA Doppler velocimetry;  
449 <32+0 weeks) and positive UmA end-diastolic flow ending in livebirth, women with an sflt1/PIGF  
450 ratio ≥85 were significantly more likely to deliver within one, two, three and four weeks from ratio  
451 measurement than women with an sflt1/PIGF ratio <85 (54). Composite neonatal morbidity and  
452 neonatal admission were also significantly higher following pregnancies with a sflt1/PIGF ratio ≥85  
453 (53.8% vs 28.6% p=0.04; 97.5% vs 67.9% p<0.01). More strikingly, in a series of 130 singleton  
454 pregnancies with SGA (AC or EFW <10<sup>th</sup> centile), fetal demise only occurred in pregnancies with a  
455 PIGF <10<sup>th</sup> centile for gestational age at any time between 16 and 36 weeks (12/65 vs 0/65,  
456 p<0.0001) (55).

457 While these studies revealed the PIGF results to the managing clinicians, similar results have been  
458 found in studies where PIGF was not revealed. The secondary analysis of STRIDER UK trial  
459 participants, mentioned above, found significant associations between pregnancy outcomes and  
460 both the sflt1/PIGF ratio and PIGF alone (40). Higher PIGF concentrations and a lower sflt1/PIGF  
461 ratios were associated with greater overall survival (PIGF coefficient 3.67, p<0.001; ratio coefficient  
462 0.51, p=0.002) and later gestation at birth (PIGF coefficient 1.4, p<0.001; ratio coefficient -0.99,  
463 p<0.001). Similarly, in a multinational case series of 411 pregnancies, PIGF <5<sup>th</sup> centile at the time of  
464 suspected FGR (AC <10<sup>th</sup> centile from 20+0 weeks) had an 87.5% sensitivity and 62.8% specificity for  
465 predicting stillbirth (56). PIGF <12 pg/ml was associated with a shorter interval to delivery than PIGF  
466 >5<sup>th</sup> centile (13.0 vs 29.5 days, p<0.0001).

467 Our finding that placental histological classification of maternal vascular malperfusion was  
468 significantly associated with lower maternal PIGF concentration and higher mean uterine artery PI at

IMPPICT\_JCI\_version\_1

469 diagnosis of early-onset FGR, but not with Uma Doppler measurements, was in keeping with the  
470 results of previous studies (56-59). Agrawal et al. have recently reported that MVM, unlike other  
471 placental pathologies, is characterised by raised mean uterine artery PI and a gradual decline in PIGF  
472 as the pregnancy progresses (57). Triunfo et al. found in SGA pregnancies (EFW <10<sup>th</sup>) identified  
473 between 30 and 34 weeks of gestation, a pattern of placental histopathology they termed 'placental  
474 underperfusion', was most strongly associated with lower PIGF, measured at the time of diagnosis  
475 (58). Benton et al. also found low PIGF to be a better predictor of placental pathology than umbilical  
476 artery resistance index or abdominal circumference centile (56).

477

#### 478 **Strengths and limitations**

479 The strengths of this multicentre study are that it was carried out prospectively in academic health  
480 science centres with fetal medicine experts trained on a common ultrasound protocol, and level 3  
481 perinatal care available for delivery. Participants and their fetuses/neonates were extensively  
482 phenotyped at study entry, for the duration of the pregnancy and postnatally, and we report  
483 temporally validated results. All pregnancies were managed according to local guidelines, although  
484 these were broadly consistent, in line with national and international guidelines (4, 16, 60, 61) and  
485 current RCT evidence (e.g. the TRUFFLE trial). This introduces variation, but potentially better  
486 reflects real-world practice and hence adds external validity. All serum analysis was carried out after  
487 pregnancy outcomes were obtained, using a proteomic discovery science approach which did not  
488 assume associations with outcome, but also included additional analysis of proteins anticipated to  
489 be related to pregnancy outcome in placental insufficiency. Placental histological classification was  
490 blinded to pregnancy outcomes and included control and non-FGR preterm placental samples, to  
491 remove some potential bias. Finally, our inclusion of stakeholders to guide model selection means  
492 that their predictive value is most important to patients and clinicians.

IMPPICT\_JCI\_version\_1

493 Our relatively narrow inclusion criteria are both a strength and a limitation, in that they have  
494 allowed us to focus on a specific clinical group but have limited our sample size and the  
495 generalisability of our findings. The sample size means our study was underpowered to demonstrate  
496 small or medium effects and our estimates have wider confidence intervals than larger studies (62).  
497 The exclusion of pregnancies <3<sup>rd</sup> centile but >600g limits the number of pregnancies from 24+6  
498 weeks of gestation to which our findings can be applied and the exclusion of pregnancies with  
499 known genetic, chromosomal, and structural differences means our findings cannot be applied to  
500 the whole spectrum of FGR. Generalisability is also limited to healthcare settings with comparable  
501 neonatal care provision and outcomes, given their impact on neonatal survival and decision making  
502 for iatrogenic preterm delivery. Clinicians managing the pregnancies were not blinded to ultrasound  
503 measurements, and indeed many management decisions will have been influenced by ultrasound  
504 findings. This could have biased the apparent associations between ultrasound variables and  
505 pregnancy outcomes, either artificially strengthening or weakening them.

506

#### 507 **Future directions**

508 Ideally, our findings should be independently and externally validated. Given the incidence of FGR  
509  $\leq 28+0$  weeks this would require another multicentre study. Further research is also needed to  
510 determine whether the use of these models would have benefit in practice, both on the  
511 psychological wellbeing of parents and on the use of health resources. Future studies to identify and  
512 validate predictive models in early-onset SGA (EFW <10<sup>th</sup> centile <32+0 weeks of gestation) would  
513 allow application to a wider population. This would complement the work currently being done in  
514 the PLANES study, which is investigating the impact of revealed PIGF in SGA from 32+0 weeks (63).  
515 Finally, our primary outcome of fetal or neonatal death provides only short-term information, and  
516 data collection for 2-year neurodevelopmental outcomes is on-going.

517

518 **Conclusion**

519 In conclusion, our study provides validated models for predicting fetal or neonatal death and fetal  
520 death or delivery  $\leq 28+0$  weeks of gestation based on ultrasound and maternal serum protein  
521 measurements at the time of diagnosis of severe early-onset FGR. The EFW z-score and umbilical  
522 artery Doppler velocimetry were the best performing ultrasound parameters, but are vulnerable to  
523 inter-rater variability, variation in formulae and reference ranges and temporal variation. The  
524 biomarker PIGF was the best performing maternal serum protein for predicting both pregnancy  
525 outcomes and maternal vascular malperfusion. This identification of a specific pathological  
526 phenotype may be useful for targeting future potential therapies.

527

528

529

530

531

532

533

534

535

536

537 **Methods**

538 This study is reported according to the 'strengthening the reporting of observational studies in  
539 epidemiology' (STROBE) guidelines (64) for cohort studies and the 'transparent reporting of a  
540 multivariable prediction model for individual prognosis or diagnosis' (TRIPOD) guidelines (65).

541 **Study design and setting:** The EVERREST Prospective Study was a multicentre prospective cohort  
542 study recruiting pregnant women from four European tertiary referral centres: University College  
Page 29

543 London Hospital, UK; University Medical Centre Hamburg-Eppendorf, Germany; Maternal-Fetal Unit  
544 Hospital Clinic Barcelona, Spain; Skane University Hospital, Lund, Sweden.

545 **Study population:** Full details of the protocol have been published previously (26). In brief, pregnant  
546 women were eligible if they had a singleton fetus with an ultrasound estimated fetal weight (EFW)  
547 <600g and <3<sup>rd</sup> centile according to local criteria between 20+0 and 26+6 weeks of gestation.  
548 Exclusion criteria were a known abnormal karyotype or major fetal structural abnormality at  
549 enrolment (66), indication for immediate delivery, preterm rupture of membranes before  
550 enrolment, maternal HIV or hepatitis B or C infection, maternal age under 18 years, any medical or  
551 psychiatric condition which compromised a woman's ability to participate and lack of capacity to  
552 consent. Pregnancies with a known congenital infection were not recruited and for the purposes of  
553 this analysis pregnancies ending in termination were excluded.

554 **Outcomes:** The primary outcome was fetal or neonatal death ( $\leq 28$  days of life). Secondary outcomes  
555 were: fetal death or delivery  $\leq 28+0$  weeks of gestation; slow fetal growth, defined as a worsening of  
556 weight deviation of  $\geq 10$  percentage points over a two-week interval (including before and after  
557 enrolment) or equivalent trajectory over a longer period (28); and the development of abnormal  
558 UmA Dopplers, defined as development of UmA PI  $> 95^{\text{th}}$  centile in pregnancies where UmA PI was  
559  $\leq 95^{\text{th}}$  centile at enrolment (27). Ascertainment for outcomes of this study was possible, at the latest,  
560 by 29 days of life. Follow-up for neonatal morbidity and infant health and neurodevelopment to the  
561 age of 2 years continues.

562 All pregnancies were managed according to the local fetal medicine unit protocols. Pre-eclampsia  
563 was defined according to International Society for the Study of Hypertension in Pregnancy (ISSHP)  
564 criteria (67), meaning that, given the presence of FGR, any woman developing new onset  
565 hypertension after 20+0 weeks of gestation was classified as having pre-eclampsia rather than  
566 pregnancy-induced hypertension. Formalin-fixed placental samples were classified according to  
567 Amsterdam consensus criteria by a single assessor (NS) (68). To minimise bias, study placental

IMPPICT\_JCI\_version\_1

568 samples were mixed with placental samples from healthy term pregnancies and pregnancies  
569 delivering spontaneously preterm, with NS blinded to pregnancy phenotype and outcome during the  
570 assessment.

571 **Ultrasound measurements:** All ultrasound examinations were performed by staff trained and  
572 validated to the common EVERREST prospective study protocol (26). At each ultrasound scan  
573 Doppler velocimetry of the umbilical artery (UmA), uterine artery (UtA), middle cerebral artery  
574 (MCA), ductus venosus (DV) and umbilical vein was performed (69). Local EFW formulae and centile  
575 charts were used to determine study eligibility, but for consistency all EFWs were recalculated using  
576 the Hadlock 3 formula (incorporating head circumference, abdominal circumference and femur  
577 length), with z-scores recalculated using the Marsal chart for descriptive data (supplementary data  
578 Equations 1-3) (29, 30). EFWs and z-scores were also recalculated using Intergrowth formulae for  
579 analysis (supplementary data Equations 4 & 5) (31). The effect of alternative Doppler reference  
580 charts was explored, with similar results to those presented (70-74).

581 **Blinding:** Maternal serum protein concentrations were not available to clinicians, participants or  
582 researchers during the pregnancy, as all samples were analysed after complete primary outcome  
583 data had been ascertained. Serum PIGF and sflt-1 concentrations were not used as part of clinical  
584 care in any of the study centres during the period of recruitment.

585 **Sample collection:** Maternal blood was collected at study enrolment in BD Vacutainer® serum  
586 separating tubes and processed according to the manufacturer's instructions. 500µl serum aliquots  
587 were frozen and stored at -80°C. Placental samples, for Amsterdam criteria categorisation, were  
588 collected from two areas of each placenta, midway between the cord insertion and margin in areas  
589 free from macroscopic infarcts or lesions. Samples were rinsed in PBS, formalin-fixed, wax-  
590 embedded, sectioned and stained with H&E.

591 **Measurement of a priori candidate biomarkers in maternal serum:** PIGF and sflt-1 concentrations  
592 were measured using Elecsys® electrochemiluminescence immunoassays on a Cobas® e411 analyser

IMPPICT\_JCI\_version\_1

593 (Roche Diagnostics). The normalised protein expression (NPX) of 90 additional proteins associated  
594 with cardiovascular disease was measured using the Olink® Cardiovascular II proximity extension  
595 assay (full list of proteins in supplementary data Table 17). In the discovery set but not the validation  
596 set VEGFA, VEGFD, VEGFR2, neuropilin 1 and endoglin were measured in triplicate using Quantikine®  
597 colorimetric sandwich ELISAs (R&D Systems).

598 **Identification of novel candidate biomarkers in maternal serum using liquid chromatography and**

599 **tandem mass spectrometry:** Five pooled serum samples were created on the following basis: (1)

600 pregnancies ending in fetal or neonatal death (2) pregnancies ending in neonatal survival with

601 delivery <37+0 weeks of gestation (3) pregnancies ending in neonatal survival with delivery 37+0

602 weeks of gestation or more (4) slow fetal growth trajectory (5) normal fetal growth trajectory.

603 Pooled serum samples were depleted of 12 high-abundance proteins using Proteome Purify™ 12

604 resin, as per the manufacturer's instructions (R&D Systems), concentrated using Vivaspin® 500 5kDa

605 Molecular Weight Cut-Off columns (GE Healthcare), reduced with 10mM tris(2-

606 carboxyethyl)phosphine hydrochloride then alkylated with 7.5mM iodoacetamide. Pooled samples

607 were digested using a trypsin/Lys-C mix, labelled with Tandem Mass Tags™ (Thermo Fisher

608 Scientific) and combined(75). The combined sample underwent two-dimensional high-performance

609 reverse-phase liquid chromatography and tandem mass spectrometry. In the first dimension,

610 samples were fractionated into 30 at high pH using a Poroshell 300 Extend C18 column (Agilent),

611 following which fractions 1-4 were combined with fractions 27-30 respectively due to low

612 abundance in the first four fractions. The second fractionation was performed on the Ultimate 3000

613 nano-liquid chromatography system using Acclaim™ PepMap™ 100 C18 pre-columns and Acclaim™

614 PepMap™ 100 C18 Nano-LC columns run in tandem with analysis on the LTQ (linear trap

615 quadrupole) Orbitrap XL™ 2.5.5 (all Thermo Fisher Scientific). A blank calibration sample was run

616 after every three fractions, and a standard sample of known mass run after every six fractions, for

617 quality control.



IMPPICT\_JCI\_version\_1

618 Proteins were identified using Proteome Discover V1.4 software (ThermoFisher Scientific) to search  
619 the human Swiss-Prot database with the Mascot search engine (Matrix Science Ltd.). Proteins were  
620 scored on variability, peptide count, ubiquity, ratio between pools and consistent trend across pools  
621 (supplementary data Tables 18 & 19). Expression pattern clusters, based on standardised and raw  
622 quantification ratios, were generated using the Graphical Proteomics Data Explorer (GPRoX)  
623 platform. Based on their scores and expression clusters, five candidate proteins were selected and  
624 measured in individual samples using ELISAs. Fibronectin, PSG1 (both R&D Systems) and HPL (DRG  
625 International) were measured in the discovery and validation sets while SAA (R&D Systems) and  
626 LNPEP (Cloud-clone) were measured in the discovery set only.

627 **Priority survey and model selection:** An online survey was sent to patients and clinicians asking their  
628 opinion on the importance of different pregnancy outcomes and, for each outcome, whether they  
629 would prioritise sensitivity or specificity. Models were selected on the basis of the survey results and  
630 the model performance metrics described below. Protein models were published online prior to the  
631 validation data analysis.

632 **Sample size:** Since this work involved discovery of novel biomarkers, a formal *a priori* sample size  
633 calculation was not possible. Before analysing the discovery set it was determined that this sample  
634 of n=63 with 21 fetal or neonatal deaths gave an 80% power to detect a standardised effect size of  
635 0.9 (large) to a significance level of 0.05 (76).

636 **Statistics:** Data analysis was performed using STATA/MP 16.1 software (StataCorp LLC, College  
637 Station, USA) unless otherwise specified. Descriptive and investigative variables were tested for  
638 skew and kurtosis (77, 78) and handled as symmetrical if there was no evidence of either. PIGF, sft1,  
639 endoglin, VEGFD, NP1, HPL, SAA and LNPEP were transformed to their natural logs and multiplex  
640 data was analysed as provided, on a log<sub>2</sub> scale. Characteristics of the discovery and validation sets  
641 were compared using chi-square tests (categorical data), Fisher's exact tests (binary data with sparse

IMPPICT\_JCI\_version\_1

642 outcomes), 2-sided t tests (symmetrical continuous data) and Mann-Whitney U tests (skewed  
643 continuous data).

644 Missing data for BMI (n=5) were imputed using chain equations. Umbilical artery (UmA) PI at  
645 enrolment was systematically missing (n=16), with most missing cases having absent or reversed  
646 end-diastolic flow (EDF, n=15). Umbilical artery Doppler velocimetry was therefore handled as an  
647 interval variable, 'UmA PI category', , where 0=UmA PI  $\leq$ 95<sup>th</sup> centile, 1=UmA >95<sup>th</sup> centile with  
648 positive EDF, 2=absent EDF, 3=reversed EDF. Where uterine artery (UtA) PI at enrolment was missing  
649 (n=10) a mean UtA PI below or above the 95<sup>th</sup> centile could be inferred in nine cases where the  
650 mean UtA PI was consistently normal (n=1) or abnormal (n=8) respectively at scans prior to and after  
651 enrolment and UtA PI values were imputed using multiple imputation. Associations between  
652 ultrasound measurements and both fetal or neonatal death and death or delivery  $\leq$ 28+0 weeks of  
653 gestation, were analysed using logistic regression. Univariate associations between protein  
654 concentrations or NPX and outcomes were assessed using 2-sided t tests, Mann-Whitney U tests and  
655 logistic regression, with Benjamini-Hochberg procedures to account for multiple comparisons.

656 **Model development:** Two-protein models for the development of abnormal UmA Dopplers and  
657 two- and three-protein models for the other three pregnancy outcomes, with internal validation  
658 using leave-one-out cross-validation (LOOCV), were compared based on AUC, specificity for 90%  
659 sensitivity, sensitivity for 90% specificity, F1 score, Matthews correlation coefficient (MCC) and  
660 precision-recall characteristics (PRROC) AUC. ROC curves were generated with the *pROC* R package  
661 (version 1.18.0, <https://cran.r-project.org/web/packages/pROC/index.html> ). 95% confidence intervals  
662 for AUCs were determined by stratified bootstrapping. PRROC curves were generated with the  
663 *MLmetrics* R package (version 1.1.1, <https://cran.r-project.org/web/packages/MLmetrics/index.html>).

664 Models with variance inflation factors of five or more were excluded using the following R package:  
665 <https://cran.r-project.org/web/packages/car/index.html> , version 3.1-0. Two-variable models  
666 predicting fetal or neonatal death and death or delivery  $\leq$ 28+0 weeks of gestation containing  
667 ultrasound parameters with or without PIGF or HPL (as the proteins showing the strongest

IMPPICT\_JCI\_version\_1

668 associations with these outcomes) were compared in the same way. Outcomes and protein models  
669 to be validated were published on the study registry prior to analysis of the validation data.

670 **Parenclitic network analysis:** Parenclitic networks of the 102 proteins were generated for each of  
671 the four pregnancy outcomes. For each outcome, two-dimensional kernel density estimations were  
672 generated for every pair-combination of variables in ‘controls’ (pregnancies without the outcome).  
673 Individual networks were then generated for each ‘case’, with linkages created if a pair-wise  
674 relationship of variables differed from the control distribution by more than a given threshold(79).  
675 These individual case networks were then combined. VEGF-A, BNP, PARP1 and melusin were  
676 included as binary variables of ‘detectable’ or ‘not detectable’. Booking body mass index (BMI) and  
677 fetal sex were included as variables in the networks, except for ‘development of abnormal Uma  
678 Dopplers’, where the sample was not large enough to accommodate them.

679 **Model validation:** Concentrations of HPL and PSG1, as measured by ELISA, and NPX values for the  
680 Olink multiplex proteins showed substantial variation in centrality and spread between the discovery  
681 and validation sets. To account for this, values of each protein were centred to a mean of 0 and  
682 scaled to an SD of 1 in the discovery set and validation set separately. These centred and scaled  
683 values were used for subsequent analyses, including model validation. Concentrations of PlGF, sflt1  
684 and fibronectin did not require transformation.

685 Models generated from the discovery set were run on data from the validation set and were  
686 considered validated if the 95% CI for the validation estimate of AUC included the LOOCV AUC  
687 estimate from the discovery set. For validated models, data from both sets were combined to give  
688 final test characteristics. Likelihood ratio tests were used to determine whether the addition of  
689 pregnancy characteristics (maternal BMI, maternal age, maternal ethnicity, fetal sex, gestational age  
690 at enrolment and pre-eclampsia at enrolment) significantly improved the validated models. Model  
691 calibration was assessed by plotting predicted probability against observed frequency of outcome.

692 **Functional interactions:** Centred and scaled data from the discovery and validation sets were  
693 combined to retest univariate associations with the primary and secondary outcomes. Proteins  
694 showing a significant association at a 5% Benjamini-Hochberg false discovery rate were explored for  
695 physical and functional interactions and for enrichment of GO biological processes, relative to the  
696 background of all proteins measured, using STRING (Swiss Institute of Bioinformatics)(32). Where no  
697 enrichment was detected shared GO biological processes were identified through comparison to the  
698 whole genome.

699 **Modelling pregnancy duration:** Protein and ultrasound measurements from the combined discovery  
700 and validation sets were tested for their association with gestational age at livebirth or diagnosis of  
701 fetal death and interval from enrolment to livebirth or diagnosis of fetal death using linear  
702 regression. Variables showing a significant association at a 1% Benjamini-Hochberg false discovery  
703 rate were used to create linear models predicting these outcomes in a stepwise fashion. Maternal  
704 age, BMI, ethnicity, gestational age at enrolment, pre-eclampsia at enrolment and fetal sex were  
705 tested for model improvement. Model fit was tested by assessing variance inflation factors for  
706 multicollinearity, assessing the distribution of the residuals for heteroscedasticity and outliers, and  
707 looking for observations with high leverage. UmA and UtA Doppler velocimetry, PIGF concentration,  
708 HPL concentration and PAPP-A NPX were tested for their associations with placental histological  
709 classification using logistic regression.

710 **Study approval:** Ethical approval was provided by the National Research Ethics Service Committee  
711 London - Stanmore in the UK (REC reference: 13/LO/1254), the Hospital Clinic of Barcelona's Clinical  
712 Research Ethics Committee in Spain (Reg: HCB/2014/0091), the Regional Ethical Review Board in  
713 Lund for Sweden, (DNr 2014/147) and the Ethics Committee of Hamburg Board of Physicians in  
714 Germany (PV4809). This study was conducted according to the Declaration of Helsinki principles and  
715 written informed consent was given by all participants before enrolment.

716

## 717 **Acknowledgements**

718 The research leading to these results has received funding from the European Union Seventh  
719 Framework Programme (FP7/2007-2013) under grant agreement no. 305823, the Rosetrees Trust  
720 and the Mitchell Charitable Trust in memory of Shoshana Mitchell Glynn. This research has been  
721 supported by the National Institute for Health Research University College London Hospitals  
722 Biomedical Research Centre (RS, NM, ALD). NRN would like to thank the support from Cancer  
723 Research UK (C12077/A26223).

724

725 This work would not have been possible without the contribution of the late Professor John Timms,  
726 Elizabeth Garrett Anderson Institute for Women's Health, University College London. His  
727 contribution to the design, conduct and analysis of the study was invaluable, and we would have  
728 been honoured to have him as a co-author. We would also like to thank all of the women and  
729 families who took part in this study as well as staff at the UCL Comprehensive Clinical Trials Unit  
730 (Anna Morka, Jade Dyer, Helen Knowles, Steve Hibbert, Kate Maclagan), Gina Buquis, Jade Okell, Dr  
731 Mark Lees, Dr Carlo Rossi, Dr Tara Krishnan, Dr Roberta Morris, Dr Sarah Guillon, Richard Gunu, Dr  
732 Eva Sedlak, Professor Alexei Zaikin and Dr Oleg Blyuss.

733 **Data access statement:** The full data set will not be made publicly available because the degree of  
734 detailed phenotyping could allow individual patient identification. Limited data sharing may be  
735 possible, with the agreement of the consortium, on request to RS or ALD.

## 736 **References**

- 737 1. Zur RL, Kingdom JC, Parks WT, Hobson SR. The Placental Basis of Fetal Growth Restriction.  
738 *Obstetrics and gynecology clinics of North America.* 2020;47(1):81-98.
- 739 2. Sun C, Groom KM, Oyston C, Chamley LW, Clark AR, James JL. The placenta in fetal growth  
740 restriction: What is going wrong? *Placenta.* 2020;96:10-8.
- 741 3. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al.  
742 Consensus definition for placental fetal growth restriction: a Delphi procedure. *Ultrasound Obstet*  
743 *Gynecol.* 2016;48(3):333-9.

- 744 4. Lees CC, Stampalija T, Baschat A, da Silva Costa F, Ferrazzi E, Figueras F, et al. ISUOG Practice  
745 Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth  
746 restriction. *Ultrasound Obstet Gynecol.* 2020;56(2):298-312.
- 747 5. Society for Maternal-Fetal Medicine, Martins JG, Biggio JR, Abuhamad A. Society for  
748 Maternal-Fetal Medicine Consult Series #52: Diagnosis and management of fetal growth restriction.  
749 *Am J Obstet Gynecol.* 2020;223(4):B2-B17.
- 750 6. Ganzevoort W, Thornton JG, Marlow N, Thilaganathan B, Arabin B, Prefumo F, et al.  
751 Comparative analysis of 2-year outcomes in GRIT and TRUFFLE trials. *Ultrasound Obstet Gynecol.*  
752 2020;55(1):68-74.
- 753 7. Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, et al. Maternal sildenafil for  
754 severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-  
755 blind trial. *Lancet Child Adolesc Health.* 2018;2(2):93-102.
- 756 8. Villar J, Restrepo-Méndez MC, McGready R, Barros FC, Victora CG, Munim S, et al.  
757 Association Between Preterm-Birth Phenotypes and Differential Morbidity, Growth, and  
758 Neurodevelopment at Age 2 Years: Results From the INTERBIO-21st Newborn Study. *JAMA Pediatr.*  
759 2021;175(5):483-93.
- 760 9. Pels A, Beune IM, van Wassenaer-Leemhuis AG, Limpens J, Ganzevoort W. Early-onset fetal  
761 growth restriction: A systematic review on mortality and morbidity. *Acta Obstet Gynecol Scand.*  
762 2020;99(2):153-66.
- 763 10. Rock CR, White TA, Piscopo BR, Sutherland AE, Miller SL, Camm EJ, et al. Cardiovascular and  
764 Cerebrovascular Implications of Growth Restriction: Mechanisms and Potential Treatments.  
765 *International journal of molecular sciences.* 2021;22(14).
- 766 11. Arigliani M, Stocco C, Valentini E, De Pieri C, Castriotta L, Ferrari ME, et al. Lung function  
767 between 8 and 15 years of age in very preterm infants with fetal growth restriction. *Pediatr Res.*  
768 2021;90(3):657-63.
- 769 12. Mappa I, Maqina P, Bitsadze V, Khizroeva J, Makatsarya A, Arduini D, et al. Cardiac function  
770 in fetal growth restriction. *Minerva Obstet Gynecol.* 2021;73(4):423-34.
- 771 13. Fernandez-Twinn DS, Hjort L, Novakovic B, Ozanne SE, Saffery R. Intrauterine programming  
772 of obesity and type 2 diabetes. *Diabetologia.* 2019;62(10):1789-801.
- 773 14. Melamed N, Baschat A, Yinon Y, Athanasiadis A, Mecacci F, Figueras F, et al. FIGO  
774 (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice  
775 advice for screening, diagnosis, and management of fetal growth restriction. *Int JGynaecol Obstet.*  
776 2021;152 Suppl 1:3-57.
- 777 15. Groom KM, David AL. The role of aspirin, heparin, and other interventions in the prevention  
778 and treatment of fetal growth restriction. *Am J Obstet Gynecol.* 2018;218(2S):S829-S40.
- 779 16. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 31: The  
780 Investigation and Management of the Small-for-Gestation-Age Fetus. London: RCOG; 2014.
- 781 17. Ormesher L, Warrander L, Liu Y, Thomas S, Simcox L, Smith GCS, et al. Risk stratification for  
782 early-onset fetal growth restriction in women with abnormal serum biomarkers: a retrospective  
783 cohort study. *Scientific reports.* 2020;10(1):22259.
- 784 18. Sovio U, Goulding N, McBride N, Cook E, Gaccioli F, Charnock-Jones DS, et al. A maternal  
785 serum metabolite ratio predicts fetal growth restriction at term. *Nat Med.* 2020;26(3):348-53.
- 786 19. Tong S, Joy Kaitu'u-Lino T, Walker SP, MacDonald TM. Blood-based biomarkers in the  
787 maternal circulation associated with fetal growth restriction. *Prenat Diagn.* 2019;39(11):947-57.
- 788 20. Romero Infante XC, Uriel M, Porras Ramírez A, Rincón Franco S. Comparison of preeclampsia  
789 and fetal growth restriction screenings at first trimester in a high-risk population. *J Obstet Gynaecol*  
790 *Res.* 2021;47(2):765-73.
- 791 21. Asvold BO, Vatten LJ, Romundstad PR, Jenum PA, Karumanchi SA, Eskild A. Angiogenic  
792 factors in maternal circulation and the risk of severe fetal growth restriction. *Am J Epidemiol.*  
793 2011;173(6):630-9.

- 794 22. Cnossen JS, Morris RK, ter Riet G, Mol BW, van der Post JA, Coomarasamy A, et al. Use of  
795 uterine artery Doppler ultrasonography to predict pre-eclampsia and intrauterine growth restriction:  
796 a systematic review and bivariable meta-analysis. *CMAJ*. 2008;178(6):701-11.
- 797 23. Harvey ME, David AL, Dyer J, Spencer R. Pregnant women's experiences and perceptions of  
798 participating in the EVERREST prospective study; a qualitative study. *BMC Pregnancy Childbirth*.  
799 2019;19(1):144.
- 800 24. Blakeley C, Smith DM, Johnstone ED, Wittkowski A. Women's lived experiences of a prenatal  
801 diagnosis of fetal growth restriction at the limits of viability: An interpretative phenomenological  
802 study. *Midwifery*. 2019;76:110-7.
- 803 25. David AL. Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth  
804 restriction. *Placenta*. 2017;59 Suppl 1:S44-S50.
- 805 26. Spencer R, Ambler G, Brodzki J, Diemert A, Figueras F, Gratacos E, et al. EVERREST  
806 prospective study: a 6-year prospective study to define the clinical and biological characteristics of  
807 pregnancies affected by severe early onset fetal growth restriction. *BMC Pregnancy Childbirth*.  
808 2017;17(1):43.
- 809 27. Schaffer AC, Staudach A. Doppler-Referenzkurven. 1997.
- 810 28. Marsal K. Obstetric management of intrauterine growth restriction. *Best Pract Res Clin*  
811 *Obstet Gynaecol*. 2009;23:857-70.
- 812 29. Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the  
813 use of head, body, and femur measurements--a prospective study. *Am J Obstet Gynecol*.  
814 1985;151(3):333-7.
- 815 30. Marsal K, Persson PH, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based  
816 on ultrasonically estimated foetal weights. *Acta Paediatr*. 1996;85(7):843-8.
- 817 31. Stirnemann J, Villar J, Salomon LJ, Ohuma E, Ruyan P, Altman DG, et al. International  
818 estimated fetal weight standards of the INTERGROWTH-21st Project. *Ultrasound Obstet Gynecol*.  
819 2017;49(4):478-86.
- 820 32. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, et al. The STRING database in  
821 2021: customizable protein-protein networks, and functional characterization of user-uploaded  
822 gene/measurement sets. *Nucleic Acids Res*. 2021;49(D1):D605-D12.
- 823 33. Mahajan D, Sharma NR, Kancharla S, Kolli P, Tripathy A, Sharma AK, et al. Role of Natural  
824 Killer Cells during Pregnancy and Related Complications. *Biomolecules*. 2022;12(1).
- 825 34. Thomas JR, Appios A, Zhao X, Dutkiewicz R, Donde M, Lee CYC, et al. Phenotypic and  
826 functional characterization of first-trimester human placental macrophages, Hofbauer cells. *J Exp*  
827 *Med*. 2021;218(1).
- 828 35. Raguema N, Moustadraf S, Bertagnolli M. Immune and Apoptosis Mechanisms Regulating  
829 Placental Development and Vascularization in Preeclampsia. *Front Physiol*. 2020;11:98.
- 830 36. Schrimpf C, Teebken OE, Wilhelmi M, Duffield JS. The role of pericyte detachment in vascular  
831 rarefaction. *J Vasc Res*. 2014;51(4):247-58.
- 832 37. Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in high-risk  
833 pregnancies. *Cochrane Database Syst Rev*. 2010(1):CD007529.
- 834 38. Morris RK, Malin G, Robson SC, Kleijnen J, Zamora J, Khan KS. Fetal umbilical artery Doppler  
835 to predict compromise of fetal/neonatal wellbeing in a high-risk population: systematic review and  
836 bivariate meta-analysis. *Ultrasound Obstet Gynecol*. 2011;37(2):135-42.
- 837 39. Baião AER, de Carvalho PRN, Moreira MEL, de Sá RAM, Junior SCG. Predictors of perinatal  
838 outcome in early-onset fetal growth restriction: A study from an emerging economy country. *Prenat*  
839 *Diagn*. 2020;40(3):373-9.
- 840 40. Sharp A, Jackson R, Cornforth C, Harrold J, Turner MA, Kenny L, et al. A prediction model for  
841 short-term neonatal outcomes in severe early-onset fetal growth restriction. *Eur J Obstet Gynecol*  
842 *Reprod Biol*. 2019;241:109-18.



- 843 41. Baschat AA, Gembruch U, Reiss I, Gortner L, Weiner CP, Harman CR. Relationship between  
844 arterial and venous Doppler and perinatal outcome in fetal growth restriction. *Ultrasound Obstet*  
845 *Gynecol.* 2000;16(5):407-13.
- 846 42. Bilardo CM, Wolf H, Stigter RH, Ville Y, Baez E, Visser GH, et al. Relationship between  
847 monitoring parameters and perinatal outcome in severe, early intrauterine growth restriction.  
848 *Ultrasound Obstet Gynecol.* 2004;23(2):119-25.
- 849 43. The investigation and management of the small-for gestational age fetus. Green-top  
850 Guideline No 31. London: Royal College of Obstetricians and Gynaecologists; 2013.
- 851 44. Thomas RL, Peng TC, Eglinton GS, Strobino DM, Johnson TR. Precision of umbilical artery  
852 Doppler studies. Intraobserver, interobserver, and biologic variability of fetal Doppler velocimetry. *J*  
853 *Ultrasound Med.* 1991;10(4):201-4.
- 854 45. Bruin CM, Ganzevoort W, Schuit E, Mensing van Charante NA, Wolf H. Inter- and intra-  
855 observer variability in fetal ductus venosus blood flow measurements in high-risk fetuses at 26-32  
856 weeks. *Eur J Obstet Gynecol Reprod Biol.* 2019;243:67-71.
- 857 46. Pasquini L, Marchi L, Gaini C, Franchi C, Mecacci F, Bilardo CM. Intra- and Interobserver  
858 Reproducibility of Third Trimester Middle Cerebral Artery Pulsatility Index Measurement: A  
859 Prospective Cross-Sectional Study. *Fetal Diagn Ther.* 2020;47(3):214-9.
- 860 47. Steller JG, Driver C, Gumina D, Peek E, Harper T, Hobbins JC, et al. Doppler velocimetry  
861 discordance between paired umbilical artery vessels and clinical implications in fetal growth  
862 restriction. *Am J Obstet Gynecol.* 2022;227(2):285 e1- e7.
- 863 48. Oros D, Ruiz-Martinez S, Staines-Urias E, Conde-Agudelo A, Villar J, Fabre E, et al. Reference  
864 ranges for Doppler indices of umbilical and fetal middle cerebral arteries and cerebroplacental ratio:  
865 systematic review. *Ultrasound Obstet Gynecol.* 2019;53(4):454-64.
- 866 49. Sarris I, Ioannou C, Chamberlain P, Ohuma E, Roseman F, Hoch L, et al. Intra- and  
867 interobserver variability in fetal ultrasound measurements. *Ultrasound Obstet Gynecol.*  
868 2012;39(3):266-73.
- 869 50. Anderson NG, Jolley IJ, Wells JE. Sonographic estimation of fetal weight: comparison of bias,  
870 precision and consistency using 12 different formulae. *Ultrasound Obstet Gynecol.* 2007;30(2):173-9.
- 871 51. Choi SKY, Gordon A, Hilder L, Henry A, Hyett JA, Brew BK, et al. Performance of six birth-  
872 weight and estimated-fetal-weight standards for predicting adverse perinatal outcome: a 10-year  
873 nationwide population-based study. *Ultrasound Obstet Gynecol.* 2021;58(2):264-77.
- 874 52. Warrander LK, Ingram E, Heazell AEP, Johnstone ED. Evaluating the accuracy and precision of  
875 sonographic fetal weight estimation models in extremely early-onset fetal growth restriction. *Acta*  
876 *Obstet Gynecol Scand.* 2020;99(3):364-73.
- 877 53. Mendoza M, Hurtado I, Bonacina E, Garcia-Manau P, Serrano B, Tur H, et al. Individual risk  
878 assessment for prenatal counseling in early-onset growth-restricted and small-for-gestational-age  
879 fetuses. *Acta Obstet Gynecol Scand.* 2021;100(3):504-12.
- 880 54. Quezada MS, Rodríguez-Calvo J, Villalaín C, Gómez-Arriaga PI, Galindo A, Herraiz I. sFlt-  
881 1/PIGF ratio and timing of delivery in early-onset fetal growth restriction with antegrade umbilical  
882 artery flow. *Ultrasound Obstet Gynecol.* 2020;56(4):549-56.
- 883 55. Shinar S, Tigert M, Agrawal S, Parks WA, Kingdom JC. Placental growth factor as a diagnostic  
884 tool for placental mediated fetal growth restriction. *Pregnancy hypertension.* 2021;25:123-8.
- 885 56. Benton SJ, McCowan LM, Heazell AE, Gynspan D, Hutcheon JA, Senger C, et al. Placental  
886 growth factor as a marker of fetal growth restriction caused by placental dysfunction. *Placenta.*  
887 2016;42:1-8.
- 888 57. Agrawal S, Parks WT, Zeng HD, Ravichandran A, Ashwal E, Windrim RC, et al. Diagnostic  
889 utility of serial circulating placental growth factor levels and uterine artery Doppler waveforms in  
890 diagnosing underlying placental diseases in pregnancies at high risk of placental dysfunction. *Am J*  
891 *Obstet Gynecol.* 2022.



- 892 58. Triunfo S, Lobmaier S, Parra-Saavedra M, Crovetto F, Peguero A, Nadal A, et al. Angiogenic  
893 factors at diagnosis of late-onset small-for-gestational age and histological placental underperfusion.  
894 *Placenta*. 2014;35(6):398-403.
- 895 59. Schiffer V, Borghans CWJ, Arts N, Bons JAP, Severens-Rijvers CAH, van Kuijk SMJ, et al. The  
896 association between first trimester placental biomarkers and placental lesions of maternal vascular  
897 malperfusion. *Placenta*. 2021;103:206-13.
- 898 60. Lausman A, Kingdom J, Gagnon R, Basso M, Bos H, Crane J, et al. Intrauterine growth  
899 restriction: screening, diagnosis, and management. *J Obstet Gynaecol Can*. 2013;35(8):741-57.
- 900 61. Perinatal Society of Australia and New Zealand and Centre of Research Excellence Stillbirth.  
901 Position statement: detection and management of fetal growth restriction in singleton pregnancies.  
902 Brisbane, Australia: Centre of Research Excellence in Stillbirth.; 2019.
- 903 62. Zeisler H, Llorba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive Value of  
904 the sFlt-1:PIGF Ratio in Women with Suspected Preeclampsia. *N Engl J Med*. 2016;374(1):13-22.
- 905 63. Gent J, Bullough S, Harrold J, Jackson R, Woolfall K, Andronis L, et al. The PLANES study: a  
906 protocol for a randomised controlled feasibility study of the placental growth factor (PIGF) blood  
907 test-informed care versus standard care alone for women with a small for gestational age fetus at or  
908 after 32 + 0 weeks' gestation. *Pilot Feasibility Stud*. 2020;6(1):179.
- 909 64. Vandembroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al.  
910 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and  
911 elaboration. *PLoS medicine*. 2007;4(10):e297.
- 912 65. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable  
913 prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. *BJOG*.  
914 2015;122(3):434-43.
- 915 66. Carvalho MHB, Brizot ML, Lopes LM, Chiba CH, Miyadahira S, Zugaib M. Detection of fetal  
916 structural abnormalities at the 11–14 week ultrasound scan. *Prenat Diagn*. 2002;22(1):1-4.
- 917 67. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, et al. The  
918 hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management  
919 recommendations for international practice. *Pregnancy hypertension*. 2018;13:291-310.
- 920 68. Khong TY, Mooney EE, Ariel I, Balmus NC, Boyd TK, Brundler MA, et al. Sampling and  
921 Definitions of Placental Lesions: Amsterdam Placental Workshop Group Consensus Statement. *Arch*  
922 *Pathol Lab Med*. 2016;140(7):698-713.
- 923 69. Bhide A, Acharya G, Bilardo CM, Brezinka C, Cafici D, Hernandez-Andrade E, et al. ISUOG  
924 practice guidelines: use of Doppler ultrasonography in obstetrics. *Ultrasound Obstet Gynecol*.  
925 2013;41:233-9.
- 926 70. Arduini D, Rizzo G. Normal values of Pulsatility Index from fetal vessels: a cross-sectional  
927 study on 1556 healthy fetuses. *J Perinat Med*. 1990;18(3):165-72.
- 928 71. Gómez O, Figueras F, Fernández S, Bannasar M, Martínez JM, Puerto B, et al. Reference  
929 ranges for uterine artery mean pulsatility index at 11–41 weeks of gestation. *Ultrasound Obstet*  
930 *Gynecol*. 2008;32(2):128-32.
- 931 72. Hofstaetter C, Dubiel M, Gudmundsson S, Marsal K. Uterine artery color Doppler assisted  
932 velocimetry and perinatal outcome. *Acta Obstet Gynecol Scand*. 1996;75(7):612-9.
- 933 73. Gudmundsson S, Marsal K. Umbilical artery and uteroplacental blood flow velocity  
934 waveforms in normal pregnancy--a cross-sectional study. *Acta Obstet Gynecol Scand*.  
935 1988;67(4):347-54.
- 936 74. Mari G, Deter RL. Middle cerebral artery flow velocity waveforms in normal and small-for-  
937 gestational-age fetuses. *Am J Obstet Gynecol*. 1992;166(4):1262-70.
- 938 75. Whitwell HJ, Worthington J, Blyuss O, Gentry-Maharaj A, Ryan A, Gunu R, et al. Improved  
939 early detection of ovarian cancer using longitudinal multimarker models. *Br J Cancer*.  
940 2020;122(6):847-56.

IMPPICT\_JCI\_version\_1

- 941 76. Cohen J. Statistical Power Analysis for Behavioural Sciences (2nd edition): Lawrence Erlbaum  
942 Associates; 1988.
- 943 77. D'Agostino R, Belanger J, D'Agostino RJ. A suggestion for using powerful and informative  
944 tests of normality. American Statistician. 1990;44:316-21.
- 945 78. Royston P. Comment on sg3.4 and an improved D'Agostino test. Stata Technical Bulletin.  
946 1991;2:16-7.
- 947 79. Whitwell HJ, Blyuss O, Menon U, Timms JF, Zaikin A. Parenclitic networks for predicting  
948 ovarian cancer. Oncotarget. 2018;9(32):22717-26.
- 949